177 related articles for article (PubMed ID: 30635767)
1. Modified BuCy is an alternative conditioning regimen for lymphoma patients undergoing autologous stem cell transplantation.
Huang H; Zhang L; Jiang Y; Liu S; Jin Z; Chen J; Xiao X; Ruan J; Zhang X; Wu D
Ann Hematol; 2019 May; 98(5):1259-1266. PubMed ID: 30635767
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and toxicity of SEAM (semustine, etoposide, cytarabine, and melphalan) conditioning regimen followed by autologous stem cell transplantation in lymphoma.
Zhang L; Yang H; Qian C; Zhou J; Zhu Q; Jiang Y; Liu S; Chen X; Xu T; Qu C; Li C; Jin Z; Chu J; Zhang X; Wu D; Huang H
Hematology; 2022 Dec; 27(1):404-411. PubMed ID: 35413224
[TBL] [Abstract][Full Text] [Related]
3. BEAM or BuCyE high-dose chemotherapy followed by autologous stem cell transplantation in non-Hodgkin's lymphoma patients: a single center comparative analysis of efficacy and toxicity.
Kim JE; Lee DH; Yoo C; Kim S; Kim SW; Lee JS; Park CJ; Huh J; Suh C
Leuk Res; 2011 Feb; 35(2):183-7. PubMed ID: 20684990
[TBL] [Abstract][Full Text] [Related]
4. Thiotepa, Etoposide, Cyclophosphamide, Cytarabine, and Melphalan (TECAM) Conditioning Regimen for Autologous Stem Cell Transplantation in Lymphoma.
Grisariu S; Shapira MY; Or R; Avni B
Clin Lymphoma Myeloma Leuk; 2018 Apr; 18(4):272-279. PubMed ID: 29500148
[TBL] [Abstract][Full Text] [Related]
5. LACE versus BEAM conditioning in relapsed and refractory lymphoma transplant: retrospective multicenter analysis of toxicity and efficacy.
Khattry N; Gupta A; Jain R; Gore A; Thippeswamy R; Jeevangi N; Kannan S; Nair R; Saikia T
Int J Hematol; 2016 Mar; 103(3):292-8. PubMed ID: 26729297
[TBL] [Abstract][Full Text] [Related]
6. Fotemustine plus etoposide, cytarabine and melphalan (FEAM) as a new conditioning regimen for lymphoma patients undergoing auto-SCT: a multicenter feasibility study.
Musso M; Scalone R; Marcacci G; Lanza F; Di Renzo N; Cascavilla N; Di Bartolomeo P; Crescimanno A; Perrone T; Pinto A
Bone Marrow Transplant; 2010 Jul; 45(7):1147-53. PubMed ID: 19898504
[TBL] [Abstract][Full Text] [Related]
7. CEAC (oral semustine, etoposide, cytarabine and cyclophosphamide) vs BEAM (carmustine, etoposide, cytarabine, and melphalan) conditioning regimen of autologous stem cell transplantation for diffuse large B-cell lymphoma: a post-hoc, propensity score-matched, cohort study in Chinese patients.
Wang T; Liu P; Xu L; Gao L; Ni X; Tang G; Chen L; Chen J; Wang L; Wang Y; Fu W; Yue W; Liu N; Li R; Lu G; Luo Y; Yang J
Ann Hematol; 2024 Feb; 103(2):575-582. PubMed ID: 37932468
[TBL] [Abstract][Full Text] [Related]
8. [A comparison of C+SCAV and SEAM conditioning regimens in efficacy and safety in autologous hematopoietic stem cell transplantation for non-Hodgkin's lymphoma patients].
Li JQ; Zhang Y; Geng HZ; Jia SX; Wu XJ; Zhou J; Zong XP; Yang Z; Chen XC; Ma C; Chen GH; Dai HP; Li CX; Wu DP
Zhonghua Xue Ye Xue Za Zhi; 2022 Aug; 43(8):668-673. PubMed ID: 36709152
[No Abstract] [Full Text] [Related]
9. Thiotepa, busulfan, and cyclophosphamide or busulfan, cyclophosphamide, and etoposide high-dose chemotherapy followed by autologous stem cell transplantation for consolidation of primary central nervous system lymphoma.
Hyung J; Hong JY; Yoon DH; Kim S; Park JS; Park CS; Lee SW; Kim JH; Ryu JS; Huh J; Suh C
Ann Hematol; 2019 Jul; 98(7):1657-1664. PubMed ID: 30989325
[TBL] [Abstract][Full Text] [Related]
10. Retrospective evaluation of the MEAM regimen as a conditioning regimen before autologous peripheral blood stem cell transplantation for lymphoma in two centers with different dosing schedules of melphalan.
Sugimoto M; Ito S; Mashima K; Umino K; Minakata D; Nakano H; Yamasaki R; Kawasaki Y; Ashizawa M; Yamamoto C; Fujiwara S; Okazuka K; Hatano K; Sato K; Oh I; Ohmine K; Suzuki T; Muroi K; Kako S; Kanda Y
Ann Hematol; 2016 Sep; 95(9):1513-9. PubMed ID: 27365141
[TBL] [Abstract][Full Text] [Related]
11. Autologous noncryopreserved hematopoietic stem cell transplant with CEAM as a modified conditioning regimen in patients with Hodgkin lymphoma: a single-center experience with a new protocol.
Ramzi M; Mohamadian M; Vojdani R; Dehghani M; Nourani H; Zakerinia M; Haghighinejad H
Exp Clin Transplant; 2012 Apr; 10(2):163-7. PubMed ID: 22432762
[TBL] [Abstract][Full Text] [Related]
12. High-dose CEB vs BEAM with autologous stem cell transplant in lymphoma.
Wang EH; Chen YA; Corringham S; Bashey A; Holman P; Ball ED; Carrier E
Bone Marrow Transplant; 2004 Oct; 34(7):581-7. PubMed ID: 15273714
[TBL] [Abstract][Full Text] [Related]
13. Lomustine, cytarabine, cyclophosphamide, etoposide - An effective conditioning regimen in autologous hematopoietic stem cell transplant for primary refractory or relapsed lymphoma: Analysis of toxicity, long-term outcome, and prognostic factors.
Gupta A; Gokarn A; Rajamanickam D; Punatar S; Thippeswamy R; Mathew L; Bagal B; Kannan S; Khattry N
J Cancer Res Ther; 2018; 14(5):926-933. PubMed ID: 30197327
[TBL] [Abstract][Full Text] [Related]
14. Fotemustine, etoposide, cytarabine, and cyclophosphamide (FEAC) conditioning regimen for autologous stem cell transplantation in lymphoma.
Lin M; Wu X; Zhang L; Li L; Wang X; Fu X; Sun Z; Zhang X; Zhu L; Yu H; Chang Y; Nan F; Yan J; Zhou Z; Shi C; Zhang M; Li X
Leuk Lymphoma; 2023 Mar; 64(3):605-612. PubMed ID: 36657436
[TBL] [Abstract][Full Text] [Related]
15. Phase II Study of Propylene Glycol-Free Melphalan Combined with Carmustine, Etoposide, and Cytarabine for Myeloablative Conditioning in Lymphoma Patients Undergoing Autologous Stem Cell Transplantation.
Cashen AF; Fletcher T; Ceriotti C; Gao F; Ghobadi A; Vij R; Stockerl-Goldstein K; DiPersio J; Abboud C
Biol Blood Marrow Transplant; 2016 Dec; 22(12):2155-2158. PubMed ID: 27575541
[TBL] [Abstract][Full Text] [Related]
16. Substitution of cyclophosphamide in the modified BuCy regimen with fludarabine is associated with increased incidence of severe pneumonia: a prospective, randomized study.
Liu DH; Xu LP; Zhang XH; Wang Y; Yan CH; Wang JZ; Wang FR; Sun YQ; Ji Y; Zhang YY; Liu KY; Huang XJ
Int J Hematol; 2013 Dec; 98(6):708-15. PubMed ID: 24242024
[TBL] [Abstract][Full Text] [Related]
17. Busulfan, cyclophosphamide, and etoposide as high-dose conditioning regimen in patients with malignant lymphoma.
Hänel M; Kröger N; Sonnenberg S; Bornhäuser M; Krüger W; Kroschinsky F; Hänel A; Metzner B; Birkmann J; Schmid B; Hoffknecht MM; Fiedler F; Ehninger G; Zander AR
Ann Hematol; 2002 Feb; 81(2):96-102. PubMed ID: 11907790
[TBL] [Abstract][Full Text] [Related]
18. Bendamustine as part of conditioning of autologous stem cell transplantation in patients with aggressive lymphoma: a phase 2 study from the GELTAMO group.
Redondo AM; Valcárcel D; González-Rodríguez AP; Suárez-Lledó M; Bello JL; Canales M; Gayoso J; Colorado M; Jarque I; Del Campo R; Arranz R; Terol MJ; Rifón JJ; Rodríguez MJ; Ramírez MJ; Castro N; Sánchez A; López-Jiménez J; Montes-Moreno S; Briones J; López A; Palomera L; López-Guillermo A; Caballero D; Martín A;
Br J Haematol; 2019 Mar; 184(5):797-807. PubMed ID: 30548583
[TBL] [Abstract][Full Text] [Related]
19. Busulfan, etoposide, cytarabine, and melphalan as a high-dose regimen for autologous stem cell transplantation in peripheral T-cell lymphomas.
Jo JC; Kim JS; Lee JH; Lee JH; Im SN; Lee SM; Yoon SS; Kim IH; Bae SH; Lee YJ; Choi Y; Lee WS
Ann Hematol; 2021 Jan; 100(1):189-196. PubMed ID: 33205337
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of Pharmacokinetics-Directed Busulfan, Cyclophosphamide, and Etoposide Conditioning and Autologous Stem Cell Transplantation for Lymphoma: Comparison of a Multicenter Phase II Study and CIBMTR Outcomes.
Flowers CR; Costa LJ; Pasquini MC; Le-Rademacher J; Lill M; Shore TB; Vaughan W; Craig M; Freytes CO; Shea TC; Horwitz ME; Fay JW; Mineishi S; Rondelli D; Mason J; Braunschweig I; Ai W; Yeh RF; Rodriguez TE; Flinn I; Comeau T; Yeager AM; Pulsipher MA; Bence-Bruckler I; Laneuville P; Bierman P; Chen AI; Kato K; Wang Y; Xu C; Smith AJ; Waller EK
Biol Blood Marrow Transplant; 2016 Jul; 22(7):1197-1205. PubMed ID: 27040394
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
